LUCD News and Press, Lucid Diagnostics Inc. From 12/12/23

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies PR Newswire Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK , Dec. 12, 2023 /PRNewswi...

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders PR Newswire PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK , Dec. 11, 2023 /...

2023-12-04 16:32:40 ET More on Lucid Diagnostics, PAVmed, etc. PAVmed Inc. (PAVM) Q3 2023 Earnings Call Transcript Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript PAVmed Q3 2023 Earnings Preview PAVmed Q3 2023 Earnings Preview Seeking A...

PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split PR Newswire PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be ...

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts PR Newswire Industry veterans join executive team as VP, Market Access and VP, Employer Markets Shaun M. O'Neil promoted to Lucid's President and COO NEW YORK , ...

2023-11-14 22:54:09 ET Lucid Diagnostics Inc. (LUCD) Q3 2023 Results Conference Call November 14, 2023 08:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle...

PAVmed Provides Business Update and Third Quarter Financial Results PR Newswire Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conf...

2023-11-14 01:06:21 ET More on Lucid Diagnostics Seeking Alpha’s Quant Rating on Lucid Diagnostics Historical earnings data for Lucid Diagnostics Financial information for Lucid Diagnostics For further details see: Lucid Diagnostics Non-GAAP EPS of...

Lucid Diagnostics Provides Business Update and Third Quarter Financial Results PR Newswire Quarterly EsoGuard ® test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be held tomorrow, November ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...